In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
Roche’s Genentech was supposed to get a priority review for its combo using Tecentriq and Avastin plus chemo in frontline lung cancer cases, with a deadline on the FDA’s decision set for Wednesday. And usually, that means a green light is on its way sooner rather than later.
But that didn’t happen.
Instead, the FDA says it will delay its decision three months so they can take into account some new information that the agency wanted to see first.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
